Kay Biotech Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.00 M
- Revenue Growth -28.59%
- Profit Growth 39.86%
- Ebitda -1.27%
- Net Worth 55.29%
- Total Assets 10.47%
About Kay Biotech
Kay Biotech Private Limited (KBPL) is a Private Limited Indian Non-Government Company incorporated in India on 15 June 2015 (Nine years and eight months 9 days old ). Its registered office is in New Delhi, Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.00 M.
Sayed Ala, Sayed Ahmed, and Sayed Sualeh serve as directors at the Company.
Company Details
- Location
New Delhi, Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24233DL2015PTC281594
- Company No.
281594
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Jun 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
What products or services does Kay Biotech Private Limited offer?
Kay Biotech Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Tablets, Pain Relief Drugs & Pharmaceuticals, Diclofenac, Nutraceuticals & Dietary Supplements, Dietary Supplements, Anti Infective Drugs & Medicines, HIV Drugs, Injectable Products, Antifungal Injection, Tablet & Syrup.
Who are the key members and board of directors at Kay Biotech?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sayed Ala  | Director | 15-Jun-2015 | Current |
| Sayed Ahmed | Director | 15-Jun-2015 | Current |
| Sayed Sualeh | Director | 15-Jun-2015 | Current |
Financial Performance of Kay Biotech.
Kay Biotech Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 28.59% decrease. The company also saw a substantial improvement in profitability, with a 39.86% increase in profit. The company's net worth Soared by an impressive increase of 55.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kay Biotech?
In 2023, Kay Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹2.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.20 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 May 2016 | Others | ₹2.00 M | Open |
How Many Employees Work at Kay Biotech?
Unlock and access historical data on people associated with Kay Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kay Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kay Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.